Pancreatic Cell News Volume 10.01 | Jan 15 2019

TOP STORY

Insulin Inhibits Glucagon Release by SGLT2-Induced Stimulation of Somatostatin Secretion

Scientists showed in mice that therapeutic concentrations of insulin inhibited glucagon secretion by an indirect mechanism mediated by stimulation of intra-islet somatostatin release. [Nat Commun] Full Article

(Ranked by impact factor of the journal)

DIABETES & PANCREATITIS

New Roles for Dopamine D₂ and D₃ Receptors in Pancreatic Beta Cell Insulin Secretion

Researchers assessed the roles of the dopamine (DA) precursor L-DOPA in β-cell DA synthesis and release in conjunction with the signaling mechanisms underlying DA’s inhibition of glucose-stimulated insulin secretion. [Mol Psychiatry] Abstract

Endoplasmic Reticulum Associated Degradation (ERAD) Has a Critical Role in Supporting Glucose-Stimulated Insulin Secretion in Pancreatic β-Cells

Scientists investigated the role of ERAD in pancreatic β-cells. Chemically induced ERAD deficiency in the rat insulinoma cell line INS-1 markedly reduced glucose-stimulated insulin secretion. [Diabetes] Abstract

MCPIP1 Regulates the Sensitivity of Pancreatic Beta-Cells to Cytokine Toxicity

Investigators examined the role of monocyte chemotactic protein-induced protein 1 (MCPIP1), a novel cytokine-induced antiinflammatory protein, in insulitis. Basal MCPIP1 expression was lower in rat vs. human islets and beta-cells. [Cell Death Dis] Full Article

HM47118A, a Novel Insulinotropic GPR119 Agonist and Potential Oral Antidiabetic Agent

HM47118A increased insulin secretion in MIN-6 cells and the proliferation of NIT-1 pancreatic β cells. The compound showed favorable pharmacokinetic profiles in all three animal models. [Diabetes Res Clin Pract] Abstract

Exendin-4 Prevented Pancreatic Beta Cells from Apoptosis in (Type I) Diabetic Mouse via Keap1-Nrf2 Signaling

The authors demonstrated that the Keap1-Nrf2-ARE pathway was stimulated by exendin-4 treatment during the development of type I diabetes mellitus (T1DM) in a murine TIDM model as well as in pancreatic β-cells. They also observed excessive reactive oxygen species production, low level of cell death, and PKC phosphorylation with exendine-4 treatment. [Exp Biol Med] Abstract

3D Cell Printing of Islet-Laden Pancreatic Tissue-Drived Extracellular Matrix Bioink Constructs for Enhancing Pancreatic Functions

Scientists suggest the pancreatic tissue-derived extracellular matrix (pdECM) as a potential candidate to recapitulate the native microenvironment in transplantable 3D pancreatic tissues. Notably, insulin secretion and maturation of insulin-producing cells derived from human pluripotent stem cells were highly up-regulated when cultured in pdECM bioink. [J Mater Chem B] Abstract

PANCREATIC CANCER

BTK Signaling Drives CD1d^hiCD5⁺ Regulatory B-cell Differentiation to Promote Pancreatic Carcinogenesis

Researchers investigated bruton’s tyrosine kinase (BTK), a key B-cell kinase, as a potential regulator of CD1d^hiCD5⁺ regulatory B cell differentiation in the pancreatic tumor microenvironment. [Oncogene] Abstract

Silencing of Long Noncoding RNA LINC00958 Prevents Tumor Initiation of Pancreatic Cancer by Acting as a Sponge of MicroRNA-330-5p to Down-Regulate PAX8

Upregulated miR-330-5p or downregulated PAX8 inhibited the epithelial mesenchymal transition process as well as the invasion and the metastasis ability of pancreatic cancer cells. Moreover, the results indicated that miR-330-5p negatively targeted PAX8 and LINC00958, ultimately showcasing its ability to bind to miR-330-5p through its interaction with AGO2. [Cancer Lett] Abstract

Identification of Candidate Diagnostic and Prognostic Biomarkers for Pancreatic Carcinoma

Survival analysis of TCGA data and clinical data suggested that TMC7, TMPRSS4, SCEL, SLC2A1, CENPF, SERPINB5 and SLC6A14 could be potential biomarkers for the prognosis of pancreatic carcinoma. [EBioMedicine] Full Article

Development of a Novel EGFR-Targeting Antibody-Drug Conjugate for Pancreatic Cancer Therapy

The in vitro and in vivo antitumor activities of RC68-based antibody-drug conjugates were evaluated in human pancreatic cancer cells and in a BXPC-3 xenograft nude mouse model, respectively. [Target Oncol] Abstract

Leptin-Elicited miRNA-342-3p Potentiates Gemcitabine Resistance in Pancreatic Ductal Adenocarcinoma

Scientists showed that expression levels of obesity-associated miR-342-3p were significantly upregulated in gemcitabine-resistant pancreatic ductal adenocarcinoma tissues and cells, and this upregulation was associated with poor post-chemotherapy prognosis. [Biochem Biophys Res Commun] Abstract

Subscribe to one of our other 19 science newsletters such as Hepatic Cell News & Intestinal Cell News.

Immunotherapy in Pancreatic Cancer: New Hope or Mission Impossible?

The authors discuss advances in immunotherapy for pancreatic cancer, as well as the challenges and prospects for personalized immune medicine. [Cancer Lett] Abstract

Insulin Analogs: Glimpse on Contemporary Facts and Future Prospective

Investigators report the comparative analysis of pharmacokinetic/pharmacodynamic profiles of various insulin analogs based on the concurrent information about clinical aspects. [Life Sci] Abstract | Graphical Abstract

Visit our reviews page to see a complete list of reviews in the pancreatic cell research field.

Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data

Tyme Technologies, Inc. announced that its management team will hold a conference call with analysts and investors to discuss SM-88 preliminary Phase II pancreatic cancer data. [Press release from Tyme Inc. discussing research to be presented at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI), San Francisco] Press Release

Rexahn Announces Presentation of RX-3117 Data

Rexahn Pharmaceuticals, Inc. announced that it will present updated preliminary safety and efficacy data from the ongoing Phase IIa clinical trial of RX-3117 in combination with ABRAXANE^® in first-line metastatic pancreatic cancer patients. [Press release from Rexahn Pharmaceuticals, Inc. discussing research to be presented at the American Society of Clinical Oncology’s Gastrointestinal Cancers Symposium (ASCO GI), San Francisco] Press Release

EMA Grants Orphan Drug Designation to Rafael Pharmaceuticals’ Devimistat (CPI-613^®) for Treatment of Metastatic Pancreatic Cancer

Rafael Pharmaceuticals, Inc. announced that the European Medicines Agency (EMA) has granted orphan drug designation to devimistat, the company’s lead altered metabolism directed platform drug candidate, for the treatment of metastatic pancreatic cancer. [Rafael Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Press Release

Rafael Pharmaceuticals Announces Initiation of Phase II Trial of CPI-613 in Combination with Modified FOLFIRINOX in Locally Advanced Pancreatic Cancer

Rafael Pharmaceuticals, Inc. announced the initiation of a Phase II open-label trial in collaboration with University Hospitals Cleveland Medical Center to evaluate the efficacy and safety of investigational drug CPI-613 in combination with modified FOLFIRINOX in patients with localized borderline and unresectable pancreatic cancer. [Rafael Pharmaceuticals, Inc. (GlobeNewswire, Inc.)] Press Release

$9 Million Supports Deep Dive into Breast, Pancreatic Cancers

Washington University School of Medicine in St. Louis has received a $9 million grant from the National Institutes of Health (NIH) to study the life histories of breast and pancreatic cancers. [Washington University in St. Louis] Press Release

Open-Access Row Prompts Editorial Board of Elsevier Journal to Resign

The editorial board of an influential scientometrics journal – the Journal of Informetrics – has resigned in protest over the open-access policies of its publisher, Elsevier, and launched a competing publication. [Nature News] Editorial

If the Shutdown Drags on at FDA, It Will Put Anticipated New Treatments in Jeopardy

The government shutdown could soon jeopardize highly anticipated new drugs from Janssen, Sanofi and Novartis for depression, diabetes and multiple sclerosis, as well as a host of other potential new therapies, according to a STAT analysis of upcoming regulatory decision dates. [STAT News] Editorial

NEW Cell Symposia: Hallmarks of Cancer
November 17-19, 2019
Seattle, Washington, United States

Visit our events page to see a complete list of events in the community.

NEW Postdoctoral Fellowships – Cancer (Albert Einstein College of Medicine of Yeshiva University)

NEW Faculty Position – Diabetes (Sanford Research)

NEW Postdoctoral Fellow – Cancer Biology (SRI Biosciences)

NEW Faculty Positions – Diabetes and Metabolism (Texas Tech University)

Research Technologist – Pancreatic Cell Research (STEMCELL Technologies Inc.)

Postdoctoral Fellowship – Developmental and Cancer Biology (University of Copenhagen)

Postdoctoral Research Associate – Stem Cells and Regenerative Medicine (King’s College London)

Postdoctoral Fellow – Neuroscience and Diabetes (The Child Health Institute of New Jersey)

Postdoctoral Research Associate – Pancreas Development (University of Illinois)

Postdoctoral Position – Stem Cells and Diabetes (A*STAR)

Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.

Have we missed an important article or publication in Pancreatic Cell News? Click here to submit!

Comments or suggestions? Submit your feedback here.